AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12200104 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact smoking cessation intervention (stop-smoking advice by cardiologist, brief counseling by nurse, provision of self-help materials, aftercare by cardiologist)
Number of subjects: 789
Study 12200104 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 789
Study 9685101 — intervention group
Group type: EXPERIMENTAL
Intervention: Count'R‐Force Tennis Elbow Brace
Number of subjects: 50
Study 9685101 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Glove Airprene Elbow Support
Number of subjects: 50
Study 9685101 — intervention group
Group type: COMPARATOR
Intervention: Placebo brace (modified DePuy Levy Clinic Patella Strap)
Number of subjects: 50
Study 9685101 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 50
Study 7540796 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation (TUNA)
Number of subjects: 50
Study 30689222 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 infusion for eight hours
Number of subjects: 37
Study 30689222 — intervention group
Group type: COMPARATOR
Intervention: T4 infusion for eight hours
Number of subjects: 37
Study 28488462 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance dentistry including occlusal equilibration (Group D)
Number of subjects: 38
Study 28488462 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Group S)
Number of subjects: 38
Study 25678302 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with mild-moderate hip osteoarthritis (n=36)
Number of subjects: 66
Study 25678302 — intervention group
Group type: COMPARATOR
Intervention: Individuals without radiographic hip osteoarthritis (n=30)
Number of subjects: 66
Study 25678302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 24394693 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coherence
Number of subjects: 72
Study 24394693 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed transfer function
Number of subjects: 72
Study 24394693 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized partial directed coherence
Number of subjects: 72
Study 21392851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/dL)
Number of subjects: 38
Study 21392851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 38
Study 20031836 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (surgery or angioplasty)
Number of subjects: 113
Study 17101640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg/d)
Number of subjects: 462
Study 17101640 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg/d)
Number of subjects: 462
Study 17101640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 462
Study 17101640 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 462
Study 16281663 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (127 patients)
Number of subjects: 248
Study 16281663 — intervention group
Group type: COMPARATOR
Intervention: Usual care (121 patients)
Number of subjects: 248
Study 11759474 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Antilysin Spofa) 2.10(6) KIU administered preoperatively and during the first hour of surgery
Number of subjects: 42
Study 11759474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 42
Study 9416856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse cyclophosphamide (CYC) with prednisone (group A)
Number of subjects: 50
Study 9416856 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide (CYC) with prednisone (group B)
Number of subjects: 50
Study 8487657 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia (287 pmol/min/m2) in obese men
Number of subjects: 17
Study 8487657 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic hyperinsulinemia in non-obese men
Number of subjects: 17
Study 8487657 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic hyperinsulinemia in obese men
Number of subjects: 17
Study 8487657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid onset and cessation of hyperinsulinemia
Number of subjects: 17
Study 3320787 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 30
Study 3320787 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 30
Study 3320787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31531707 — intervention group
Group type: EXPERIMENTAL
Intervention: MILK MINERALS + PROTEIN
Number of subjects: 32
Study 31531707 — intervention group
Group type: EXPERIMENTAL
Intervention: PROTEIN
Number of subjects: 32
Study 31531707 — intervention group
Group type: COMPARATOR
Intervention: MILK MINERALS
Number of subjects: 32
Study 31531707 — intervention group
Group type: COMPARATOR
Intervention: CALCITR
Number of subjects: 32
Study 29486367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 150,000 IU vitamin D3
Number of subjects: 40
Study 29486367 — intervention group
Group type: COMPARATOR
Intervention: Daily dose of 5000 IU vitamin D3
Number of subjects: 40
Study 28069076 — intervention group
Group type: EXPERIMENTAL
Intervention: 55-g rye porridge
Number of subjects: 21
Study 28069076 — intervention group
Group type: COMPARATOR
Intervention: Wheat bread (control)
Number of subjects: 21
Study 28069076 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath hydrogen
Number of subjects: 21
Study 25239343 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgisis Gold
Number of subjects: 402
Study 25239343 — intervention group
Group type: COMPARATOR
Intervention: Suture closure alone
Number of subjects: 402
Study 22024170 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 186
Study 20415695 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion control tool
Number of subjects: 130
Study 18979160 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 300,000 IU cholecalciferol
Number of subjects: 28
Study 18979160 — intervention group
Group type: COMPARATOR
Intervention: 800 IU daily cholecalciferol
Number of subjects: 28
Study 15959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg
Number of subjects: 0
Study 15959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU
Number of subjects: 0
Study 15959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg and Vitamin E 400 IU
Number of subjects: 0
Study 15959426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12773957 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl oestradiol
Number of subjects: 18
Study 12773957 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta oestradiol
Number of subjects: 18
Study 12773957 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl oestradiol, conjugated equine oestrogen, oestradiol valerate
Number of subjects: 18
Study 12773957 — intervention group
Group type: COMPARATOR
Intervention: Oral oestrogen
Number of subjects: 18
Study 12773957 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestrogen
Number of subjects: 18
Study 10338065 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol
Number of subjects: 251
Study 10338065 — intervention group
Group type: COMPARATOR
Intervention: 25 microg misoprostol
Number of subjects: 251
Study 8568424 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude cervical manipulation twice/wk for 3 wk
Number of subjects: 39
Study 8568424 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice/wk for 3 wk
Number of subjects: 39
Study 1814714 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji II/G‐C Dental)
Number of subjects: 19
Study 1814714 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Ketac Fil/ESPE)
Number of subjects: 19
Study 1814714 — intervention group
Group type: COMPARATOR
Intervention: Sandwich restoration (Lining Cement/G‐C Dental)
Number of subjects: 19
Study 1814714 — intervention group
Group type: COMPARATOR
Intervention: Sandwich restoration (Ketac Bond/ESPE)
Number of subjects: 19
Study 7025171 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional toothbrush with modified handle
Number of subjects: 21
Study 7025171 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 21
Study 7025171 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-stall attached to a normal toothbrush
Number of subjects: 21
Study 31669890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (ld-IL2) combined with conventional therapy in 35 patients
Number of subjects: 71
Study 31669890 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only in 26 patients
Number of subjects: 71
Study 31669890 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 71
Study 31669890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings in PM/DM
Number of subjects: 71
Study 29603865 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste (Sorriso Dentes Brancos, Colgate Luminous White, Close up White Now)
Number of subjects: 30
Study 29603865 — intervention group
Group type: COMPARATOR
Intervention: Non-whitening toothpaste (SDB)
Number of subjects: 30
Study 26284983 — intervention group
Group type: EXPERIMENTAL
Intervention: Small ball size training group
Number of subjects: 22
Study 26284983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bigger ball size training group
Number of subjects: 22
Study 26284983 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study 24139833 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 72
Study 24139833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 72
Study 24139833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 72
Study 24139833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 72
Study 22315364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6729
Study 20558004 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch (HES)
Number of subjects: 26
Study 20558004 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid (Hartmann's solution)
Number of subjects: 26
Study 17401606 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting medications for ADHD
Number of subjects: 0
Study 17401606 — intervention group
Group type: COMPARATOR
Intervention: Cost-utility analysis
Number of subjects: 0
Study 17401606 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluations
Number of subjects: 0
Study 14762867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) at a dose of 10mg/kg/h
Number of subjects: 127
Study 14762867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (AP) with a loading dose of 2 x 10(6) KIU followed by an infusion of 500,000 KIU/h
Number of subjects: 127
Study 11297752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fatty acids (MUFA) and marine n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 25
Study 11297752 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet rich in complex carbohydrates and dietary fiber
Number of subjects: 25
Study 9395119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.15% triclosan/0.3% zinc citrate
Number of subjects: 15
Study 9395119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.15% triclosan
Number of subjects: 15
Study 9395119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.5% zinc citrate
Number of subjects: 15
Study 9395119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS/PG (1:8)
Number of subjects: 15
Study 9395119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS
Number of subjects: 15
Study 7514366 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of risperidone
Number of subjects: 388
Study 7514366 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of risperidone
Number of subjects: 388
Study 7514366 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of risperidone
Number of subjects: 388
Study 7514366 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of risperidone
Number of subjects: 388
Study 7514366 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of haloperidol
Number of subjects: 388
Study 7514366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 3286831 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous MTX-FU therapy (MTX 200 mg/m2 IV, FU 600 mg/m2 IV)
Number of subjects: 113
Study 3286831 — intervention group
Group type: COMPARATOR
Intervention: Sequential MTX-FU therapy (MTX 200 mg/m2 IV, FU 600 mg/m2 IV)
Number of subjects: 113
Study 28340306 — intervention group
Group type: COMPARATOR
Intervention: Group I (no PEEP)
Number of subjects: 105
Study 28340306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (PEEP 5 cmH2O)
Number of subjects: 105
Study 28340306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (PEEP 8 cmH2O)
Number of subjects: 105
Study 27716600 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 69
Study 27716600 — intervention group
Group type: COMPARATOR
Intervention: Perforator
Number of subjects: 69
Study 25522389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse RUL ECT (8 times seizure threshold)
Number of subjects: 102
Study 25522389 — intervention group
Group type: COMPARATOR
Intervention: Brief pulse RUL ECT (5 times seizure threshold)
Number of subjects: 102
Study 22516146 — intervention group
Group type: COMPARATOR
Intervention: General Hospital (GH) control group
Number of subjects: 272
Study 22516146 — intervention group
Group type: COMPARATOR
Intervention: General Practice (GP) control group
Number of subjects: 272
Study 20180789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before breakfast
Number of subjects: 48
Study 20180789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before lunch
Number of subjects: 48
Study 20180789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before dinner
Number of subjects: 48
Study 20180789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before evening snack
Number of subjects: 48
Study 17629999 — intervention group
Group type: EXPERIMENTAL
Intervention: Protak (Group A)
Number of subjects: 600
Study 17629999 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoANCHOR (Group B)
Number of subjects: 600
Study 17629999 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS (Group C)
Number of subjects: 600
Study 17629999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissucol (Group D)
Number of subjects: 600
Study 16183652 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety programme delivered by an occupational therapist (n = 100)
Number of subjects: 391
Study 16183652 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme prescribed at home by a physiotherapist plus vitamin D supplementation (n = 97)
Number of subjects: 391
Study 16183652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (n = 98)
Number of subjects: 391
Study 16183652 — intervention group
Group type: COMPARATOR
Intervention: Social visits (n = 96)
Number of subjects: 391
Study 16183652 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety programme
Number of subjects: 391
Study 16183652 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme with vitamin D supplementation
Number of subjects: 391
Study 11840054 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic nursing case management
Number of subjects: 0
Study 11840054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10341274 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265
Study 10341274 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study 8942890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied topically once daily for 12 months
Number of subjects: 198
Study 8942890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 198
Study 1827095 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg 12‐hourly for 7‐14 days
Number of subjects: 125
Study 1827095 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 250 mg 6‐hourly for 7‐14 days
Number of subjects: 125
Study 7083750 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 18
Study 7083750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 7083750 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and Propranolol (combined)
Number of subjects: 18
Study 7083750 — intervention group
Group type: COMPARATOR
Intervention: Control (age‐matched normal subjects)
Number of subjects: 18
Study 31547205 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily physical activity level (PAL)
Number of subjects: 14
Study 31547205 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-to-day variations in PAL (SD of PAL)
Number of subjects: 14
Study 28660441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-resveratrol drug matrix-coated balloon catheter (DCB)
Number of subjects: 153
Study 28660441 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 153
Study 26455138 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D external fixators
Number of subjects: 45
Study 26455138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nails
Number of subjects: 45
Study 26455138 — intervention group
Group type: COMPARATOR
Intervention: Plate
Number of subjects: 45
Study 24560554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-plane clear corneal incision created using a 150 kHz femtosecond laser
Number of subjects: 0
Study 24560554 — intervention group
Group type: COMPARATOR
Intervention: Single-plane angled clear corneal incision created using disposable knives
Number of subjects: 0
Study 24560554 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 0
Study 23051145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (10 minutes of forearm ischemia and reperfusion)
Number of subjects: 36
Study 23051145 — intervention group
Group type: COMPARATOR
Intervention: No ischemic preconditioning
Number of subjects: 36
Study 19168907 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coherence interferometry (PCI)
Number of subjects: 205
Study 19168907 — intervention group
Group type: COMPARATOR
Intervention: Applanation ultrasound biometry (AUS)
Number of subjects: 205
Study 17419885 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-controlled training during single leg squat (SLS) exercise
Number of subjects: 15
Study 17419885 — intervention group
Group type: COMPARATOR
Intervention: Single leg squat (SLS) exercise without feedback
Number of subjects: 15
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by physician and pharmacist
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by physician only
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by pharmacist only
Number of subjects: 712
Study 15040645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic health-related quality of life
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom profile and side effects from antihypertensive drugs
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of emergency department visits and hospitalizations
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with physicians and pharmacists
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy compliance
Number of subjects: 712
Study 15040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care charges
Number of subjects: 712
Study 11782828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with SCI
Number of subjects: 310
Study 11782828 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied mothers
Number of subjects: 310
Study 9437974 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical neurosensory test (NST) for LN injuries
Number of subjects: 130
Study 9437974 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical neurosensory test (NST) for IAN injuries
Number of subjects: 130
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for gonorrhea (cefixime, ciprofloxacin, ofloxacin)
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for chlamydia (azithromycin)
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for chancroid (azithromycin)
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy for pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole)
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-applied therapy for genital warts (podofilox)
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis therapy
Number of subjects: 0
Study 8042129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of sequelae and transmission
Number of subjects: 0
Study 3542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidometacin (400 mg p.o.)
Number of subjects: 20